Prehypertension in disease-free adults : a marker for an adverse cardiometabolic risk profile

Cardiovascular disease (CVD) is the leading cause of death worldwide. Understandably, cardiometabolic risk assessment is an integral component of every adult health evaluation. Customary assessment measures are, however, inadequate: as two-thirds of sudden cardiac deaths occur in clinically healthy...

Full description

Saved in:
Bibliographic Details
Published inHypertension research Vol. 33; no. 9; pp. 905 - 910
Main Authors Gupta, Alok K, McGlone, Meghan, Greenway, Frank L, Johnson, William D
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.09.2010
Subjects
Online AccessGet full text
ISSN0916-9636
1348-4214
1348-4214
DOI10.1038/hr.2010.91

Cover

Abstract Cardiovascular disease (CVD) is the leading cause of death worldwide. Understandably, cardiometabolic risk assessment is an integral component of every adult health evaluation. Customary assessment measures are, however, inadequate: as two-thirds of sudden cardiac deaths occur in clinically healthy individuals. Novel indicators favoring early recognition of adverse cardiometabolic risk in disease-free adults are clearly needed. Clinically healthy disease-free adults with prehypertension (PreHTN: BP120–139/80–89 mm Hg) have an adverse cardiometabolic risk profile. A statistical analysis of disease-free adult NHANES participants was conducted from 1999 to 2006. Overall prevalence of PreHTN in disease-free adults was 36.3%. Prevalence was higher in men ( P <0.001) increasing with age up to 70 years ( P <0.001). Prevalence correlated strongly with indicators of adverse cardiometabolic risk profile: it was higher with increasing body mass index (BMI) and waist circumference (WC) ( P <0.001 for both). Means were significantly higher for BMI, WC, glucose, insulin, hemoglobin A1c, homeostasis model assessment, pulse pressure, C-reactive protein, total cholesterol and triglycerides in subjects with PreHTN ( vs. desirable BP: P <0.05 for all). Prevalence of two or more unfavorable risk factors (other than high BP) was 30% higher in disease-free adults with PreHTN vs. desirable BP (prevalence ratio: 1.30; 95% CI: 1.22, 1.39). Detection of PreHTN (a precursor for subsequent HTN), during annual health maintenance in disease-free adults, (especially with one or more of the recognized CVD risk correlates), could become an early marker of adverse cardiometabolic risk profile. Clinical care designed to prevent progression from PreHTN to HTN (JNC 7 recommendation) may attenuate risk.
AbstractList Cardiovascular disease (CVD) is the leading cause of death worldwide. Understandably, cardiometabolic risk assessment is an integral component of every adult health evaluation. Customary assessment measures are, however, inadequate: as two-thirds of sudden cardiac deaths occur in clinically healthy individuals. Novel indicators favoring early recognition of adverse cardiometabolic risk in disease-free adults are clearly needed. Clinically healthy disease-free adults with prehypertension (PreHTN: BP120–139/80–89 mm Hg) have an adverse cardiometabolic risk profile. A statistical analysis of disease-free adult NHANES participants was conducted from 1999 to 2006. Overall prevalence of PreHTN in disease-free adults was 36.3%. Prevalence was higher in men ( P <0.001) increasing with age up to 70 years ( P <0.001). Prevalence correlated strongly with indicators of adverse cardiometabolic risk profile: it was higher with increasing body mass index (BMI) and waist circumference (WC) ( P <0.001 for both). Means were significantly higher for BMI, WC, glucose, insulin, hemoglobin A1c, homeostasis model assessment, pulse pressure, C-reactive protein, total cholesterol and triglycerides in subjects with PreHTN ( vs. desirable BP: P <0.05 for all). Prevalence of two or more unfavorable risk factors (other than high BP) was 30% higher in disease-free adults with PreHTN vs. desirable BP (prevalence ratio: 1.30; 95% CI: 1.22, 1.39). Detection of PreHTN (a precursor for subsequent HTN), during annual health maintenance in disease-free adults, (especially with one or more of the recognized CVD risk correlates), could become an early marker of adverse cardiometabolic risk profile. Clinical care designed to prevent progression from PreHTN to HTN (JNC 7 recommendation) may attenuate risk.
Cardiovascular disease (CVD) is the leading cause of death worldwide. Understandably, cardiometabolic risk assessment is an integral component of every adult health evaluation. Customary assessment measures are, however, inadequate: as two-thirds of sudden cardiac deaths occur in clinically healthy individuals. Novel indicators favoring early recognition of adverse cardiometabolic risk in disease-free adults are clearly needed. Clinically healthy disease-free adults with prehypertension (PreHTN: BP120-139/80-89 mm Hg) have an adverse cardiometabolic risk profile. A statistical analysis of disease-free adult NHANES participants was conducted from 1999 to 2006. Overall prevalence of PreHTN in disease-free adults was 36.3%. Prevalence was higher in men (P<0.001) increasing with age up to 70 years (P<0.001). Prevalence correlated strongly with indicators of adverse cardiometabolic risk profile: it was higher with increasing body mass index (BMI) and waist circumference (WC) (P<0.001 for both). Means were significantly higher for BMI, WC, glucose, insulin, hemoglobin A1c, homeostasis model assessment, pulse pressure, C-reactive protein, total cholesterol and triglycerides in subjects with PreHTN (vs. desirable BP: P<0.05 for all). Prevalence of two or more unfavorable risk factors (other than high BP) was 30% higher in disease-free adults with PreHTN vs. desirable BP (prevalence ratio: 1.30; 95% CI: 1.22, 1.39). Detection of PreHTN (a precursor for subsequent HTN), during annual health maintenance in disease-free adults, (especially with one or more of the recognized CVD risk correlates), could become an early marker of adverse cardiometabolic risk profile. Clinical care designed to prevent progression from PreHTN to HTN (JNC 7 recommendation) may attenuate risk.Cardiovascular disease (CVD) is the leading cause of death worldwide. Understandably, cardiometabolic risk assessment is an integral component of every adult health evaluation. Customary assessment measures are, however, inadequate: as two-thirds of sudden cardiac deaths occur in clinically healthy individuals. Novel indicators favoring early recognition of adverse cardiometabolic risk in disease-free adults are clearly needed. Clinically healthy disease-free adults with prehypertension (PreHTN: BP120-139/80-89 mm Hg) have an adverse cardiometabolic risk profile. A statistical analysis of disease-free adult NHANES participants was conducted from 1999 to 2006. Overall prevalence of PreHTN in disease-free adults was 36.3%. Prevalence was higher in men (P<0.001) increasing with age up to 70 years (P<0.001). Prevalence correlated strongly with indicators of adverse cardiometabolic risk profile: it was higher with increasing body mass index (BMI) and waist circumference (WC) (P<0.001 for both). Means were significantly higher for BMI, WC, glucose, insulin, hemoglobin A1c, homeostasis model assessment, pulse pressure, C-reactive protein, total cholesterol and triglycerides in subjects with PreHTN (vs. desirable BP: P<0.05 for all). Prevalence of two or more unfavorable risk factors (other than high BP) was 30% higher in disease-free adults with PreHTN vs. desirable BP (prevalence ratio: 1.30; 95% CI: 1.22, 1.39). Detection of PreHTN (a precursor for subsequent HTN), during annual health maintenance in disease-free adults, (especially with one or more of the recognized CVD risk correlates), could become an early marker of adverse cardiometabolic risk profile. Clinical care designed to prevent progression from PreHTN to HTN (JNC 7 recommendation) may attenuate risk.
Cardiovascular disease (CVD) is the leading cause of death worldwide. Understandably, cardiometabolic risk assessment is an integral component of every adult health evaluation. Customary assessment measures are, however, inadequate: as two-thirds of sudden cardiac deaths occur in clinically healthy individuals. Novel indicators favoring early recognition of adverse cardiometabolic risk in disease-free adults are clearly needed. Clinically healthy disease-free adults with prehypertension (PreHTN: BP120-139/80-89 mm Hg) have an adverse cardiometabolic risk profile. A statistical analysis of disease-free adult NHANES participants was conducted from 1999 to 2006. Overall prevalence of PreHTN in disease-free adults was 36.3%. Prevalence was higher in men (P<0.001) increasing with age up to 70 years (P<0.001). Prevalence correlated strongly with indicators of adverse cardiometabolic risk profile: it was higher with increasing body mass index (BMI) and waist circumference (WC) (P<0.001 for both). Means were significantly higher for BMI, WC, glucose, insulin, hemoglobin A1c, homeostasis model assessment, pulse pressure, C-reactive protein, total cholesterol and triglycerides in subjects with PreHTN (vs. desirable BP: P<0.05 for all). Prevalence of two or more unfavorable risk factors (other than high BP) was 30% higher in disease-free adults with PreHTN vs. desirable BP (prevalence ratio: 1.30; 95% CI: 1.22, 1.39). Detection of PreHTN (a precursor for subsequent HTN), during annual health maintenance in disease-free adults, (especially with one or more of the recognized CVD risk correlates), could become an early marker of adverse cardiometabolic risk profile. Clinical care designed to prevent progression from PreHTN to HTN (JNC 7 recommendation) may attenuate risk.
Author MCGLONE Meghan
GREENWAY Frank L
JOHNSON William D
GUPTA Alok K
Author_xml – sequence: 1
  givenname: Alok K
  surname: Gupta
  fullname: Gupta, Alok K
  email: alok.gupta@pbrc.edu
  organization: Pennington Biomedical Research Center, Louisiana State University System
– sequence: 2
  givenname: Meghan
  surname: McGlone
  fullname: McGlone, Meghan
  organization: Pennington Biomedical Research Center, Louisiana State University System
– sequence: 3
  givenname: Frank L
  surname: Greenway
  fullname: Greenway, Frank L
  organization: Pennington Biomedical Research Center, Louisiana State University System
– sequence: 4
  givenname: William D
  surname: Johnson
  fullname: Johnson, William D
  organization: Pennington Biomedical Research Center, Louisiana State University System
BackLink https://cir.nii.ac.jp/crid/1571417125954476928$$DView record in CiNii
https://www.ncbi.nlm.nih.gov/pubmed/20535113$$D View this record in MEDLINE/PubMed
BookMark eNptkE1rFTEUhoNU7G114w-QLARBmZrvmXQnxS8o6EKXEjLJGW_aucn1ZEbovzeXW11INzmEPOc9Oc8ZOcklAyHPObvgTA5vt3ghWLtY_ohsuFRDpwRXJ2TDLDedNdKckrNabxgTg7b8CTkVTEvNudyQH18Rtnd7wAVyTSXTlGlMFXyFbkIA6uM6L5VeUk93Hm8B6VSQ-twefgNWoMFjTGUHix_LnALFVG_pHsuUZnhKHk9-rvDsvp6T7x_ef7v61F1_-fj56t11FxTnSycNZ0bI0YCGIKK1LFhmou7b1-WozRR7PcAY5Nhry7RQOvbeMCnB2KhGkOfk1TG3zf21Ql3cLtUA8-wzlLW6XktrVbPRyBf35DruILo9prbWnftrpAGvj0DAUivC9A_hzB10uy26g25neYPZf3BIi1-axwV9mh9ueXNsqS03_wR0N2XF3Ow8TL880jmlln04ue654j0X2mqlemPFIP8AXoSZwA
CitedBy_id crossref_primary_10_2337_dc10_1829
crossref_primary_10_1161_JAHA_116_003917
crossref_primary_10_1161_JAHA_120_016804
crossref_primary_10_3390_ijerph15112571
crossref_primary_10_1016_j_imbio_2016_09_004
crossref_primary_10_1016_j_numecd_2012_01_006
crossref_primary_10_1097_HJH_0000000000001940
crossref_primary_10_1080_08037051_2016_1182855
crossref_primary_10_1097_WNR_0000000000000019
crossref_primary_10_5812_ircmj_59911
crossref_primary_10_1161_HYPERTENSIONAHA_116_09004
crossref_primary_10_1038_s41371_020_00417_z
crossref_primary_10_1161_CIR_0000000000000152
crossref_primary_10_1161_CIR_0000000000000350
crossref_primary_10_1155_2019_1764079
crossref_primary_10_15829_1560_4071_2020_3_3786
crossref_primary_10_1080_10641963_2017_1334794
crossref_primary_10_1371_journal_pone_0165264
crossref_primary_10_4061_2011_605359
crossref_primary_10_18705_1607_419X_2012_18_6_522_530
crossref_primary_10_3109_08037051_2012_716580
crossref_primary_10_1371_journal_pone_0061796
crossref_primary_10_14260_jemds_159
crossref_primary_10_3390_healthcare12020271
crossref_primary_10_1097_HJH_0000000000000646
crossref_primary_10_1155_2023_2139634
crossref_primary_10_1139_cjpp_2020_0520
crossref_primary_10_1186_s13098_015_0074_8
crossref_primary_10_1016_j_heliyon_2023_e13438
crossref_primary_10_1097_HJH_0000000000003480
crossref_primary_10_1016_j_jand_2014_10_013
crossref_primary_10_1161_01_cir_0000441139_02102_80
crossref_primary_10_1097_HJH_0b013e32835b8d22
crossref_primary_10_1111_jch_12218
crossref_primary_10_1186_1475_2840_10_104
crossref_primary_10_1093_ajh_hpy148
crossref_primary_10_1093_ajh_hpv156
crossref_primary_10_1093_eurheartj_ehy339
crossref_primary_10_1161_CIR_0000000000000485
crossref_primary_10_1249_MSS_0000000000003291
crossref_primary_10_1177_00469580241246968
crossref_primary_10_1038_jhh_2016_42
crossref_primary_10_1038_s12276_019_0253_z
crossref_primary_10_1186_s12872_023_03365_x
crossref_primary_10_1093_eurheartj_eht151
crossref_primary_10_1111_jch_14888
crossref_primary_10_1016_j_jep_2015_01_023
crossref_primary_10_1016_j_medici_2015_10_003
crossref_primary_10_1186_1756_0500_5_386
crossref_primary_10_1159_000330716
crossref_primary_10_1186_1471_2458_13_730
crossref_primary_10_3109_08037051_2013_812549
crossref_primary_10_3389_fpubh_2022_898457
crossref_primary_10_1097_01_hjh_0000431740_32696_cc
crossref_primary_10_1038_s41390_024_03472_1
crossref_primary_10_1038_jhh_2017_69
crossref_primary_10_1038_s41371_017_0026_x
crossref_primary_10_1371_journal_pone_0120366
crossref_primary_10_1016_j_jep_2012_10_057
crossref_primary_10_1161_JAHA_115_002073
crossref_primary_10_3389_fcvm_2024_1300319
crossref_primary_10_4103_jfmpc_jfmpc_408_24
crossref_primary_10_18705_1607_419X_2017_23_3_243_252
crossref_primary_10_1038_hr_2010_267
crossref_primary_10_4103_njcp_njcp_240_18
Cites_doi 10.1016/S0140-6736(01)06710-1
10.1016/j.annepidem.2007.11.013
10.1186/1471-2261-8-20
10.1161/01.CIR.85.1.37
10.1291/hypres.31.1323
10.1161/CIRCULATIONAHA.106.675355
10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
10.1097/MCA.0b013e3282f3fbde
10.1016/j.ecl.2004.03.002
10.2337/dc05-1902
10.32725/jab.2006.001
10.1001/jama.289.19.2560
10.1093/ajcn/83.6.1237
10.1016/j.amjcard.2004.08.026
10.1161/01.ATV.12.11.1336
10.1001/jama.285.19.2486
10.1161/HYPERTENSIONAHA.109.129031
10.1097/HJH.0b013e328323ad89
10.32725/jab.2006.007
10.1038/jhh.2008.32
10.1097/FJC.0b013e3181a02238
10.1016/j.amjmed.2007.06.006
10.1038/ajh.2008.335
10.1016/S0140-6736(02)11911-8
10.1016/j.amjcard.2006.08.041
10.1038/ajh.2008.212
10.1161/01.CIR.55.5.767
10.1186/1471-2458-8-108
10.1016/S0140-6736(09)60318-4
ContentType Journal Article
Copyright The Japanese Society of Hypertension 2010
Copyright_xml – notice: The Japanese Society of Hypertension 2010
DBID RYH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1038/hr.2010.91
DatabaseName CiNii Complete
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1348-4214
EndPage 910
ExternalDocumentID 20535113
10_1038_hr_2010_91
10026711056
Genre Journal Article
GroupedDBID ---
-Q-
0R~
29I
39C
4.4
406
53G
5GY
70F
7X7
AANZL
AASML
ABAKF
ABAWZ
ABBRH
ABDBE
ABFSG
ABJNI
ABLJU
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACMFV
ACMJI
ACRQY
ACSTC
ACZOJ
ADBBV
AEFQL
AEJRE
AEMSY
AENEX
AESKC
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFHIU
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AHWEU
AIGIU
AILAN
AIXLP
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ATHPR
AXYYD
AYFIA
BKKNO
CS3
DNIVK
DPUIP
DU5
E3Z
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMOBN
F5P
FDQFY
FERAY
FIZPM
FSGXE
FYUFA
GX1
HZ~
IWAJR
JSH
JSO
JZLTJ
NQJWS
O9-
OK1
P2P
RNT
RNTTT
ROL
RYH
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TSG
XSB
.55
2WC
3V.
88E
8FI
8FJ
AACDK
AATNV
AAZLF
ABUWG
ADHDB
AFKRA
BAWUL
BENPR
BPHCQ
BVXVI
CCPQU
DIK
FIGPU
HMCUK
JSF
KQ8
LGEZI
LOTEE
M1P
NADUK
NAO
NXXTH
PQQKQ
PROAC
PSQYO
RJT
RZJ
TKC
TR2
UKHRP
W2D
X7M
AAYXX
CITATION
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PHGZM
PHGZT
PJZUB
PPXIY
7X8
ID FETCH-LOGICAL-c411t-3610623b6e5ec2d990c906d576363b56fd758ebc3b75905245d7a6033e69d4be3
ISSN 0916-9636
1348-4214
IngestDate Fri Sep 05 14:57:00 EDT 2025
Mon Jul 21 06:04:15 EDT 2025
Thu Apr 24 23:12:35 EDT 2025
Tue Jul 01 04:12:18 EDT 2025
Fri Feb 21 02:43:32 EST 2025
Thu Jun 26 23:45:50 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords CRP
metabolic syndrome
waist circumference
insulin resistance
BMI
Language English
License http://www.springer.com/tdm
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c411t-3610623b6e5ec2d990c906d576363b56fd758ebc3b75905245d7a6033e69d4be3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.nature.com/articles/hr201091.pdf
PMID 20535113
PQID 753994916
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_753994916
pubmed_primary_20535113
crossref_primary_10_1038_hr_2010_91
crossref_citationtrail_10_1038_hr_2010_91
springer_journals_10_1038_hr_2010_91
nii_cinii_1571417125954476928
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-09-01
PublicationDateYYYYMMDD 2010-09-01
PublicationDate_xml – month: 09
  year: 2010
  text: 2010-09-01
  day: 01
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Hypertension research
PublicationTitleAbbrev Hypertens Res
PublicationTitleAlternate Hypertens Res
PublicationTitle_FL Hypertens Res
PublicationYear 2010
Publisher Nature Publishing Group UK
Publisher_xml – name: Nature Publishing Group UK
References BFhr201091_CR30
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (BFhr201091_CR13) 2001; 285
BFhr201091_CR14
V Manninen (BFhr201091_CR8) 1992; 85
JR Patsch (BFhr201091_CR6) 1992; 12
KG Alberti (BFhr201091_CR12) 1998; 15
AV Chobanian (BFhr201091_CR15) 2003; 289
SS Ganguly (BFhr201091_CR29) 2008; 8
J St-Pierre (BFhr201091_CR4) 2007; 99
D Yu (BFhr201091_CR34) 2009; 53
G Reaven (BFhr201091_CR11) 2004; 33
BFhr201091_CR17
Q Gu (BFhr201091_CR23) 2008; 18
BFhr201091_CR18
E Corrado (BFhr201091_CR33) 2008; 19
S Lewington (BFhr201091_CR1) 2002; 360
C Nielson (BFhr201091_CR9) 2006; 29
AG Mainous (BFhr201091_CR22) 2004; 94
SM Haffner (BFhr201091_CR5) 2007; 120
Y Ishikawa (BFhr201091_CR25) 2008; 31
F Halberg (BFhr201091_CR32) 2006; 4
AK Gupta (BFhr201091_CR10) 2008; 22
GM Reaven (BFhr201091_CR16) 2006; 83
A Onat (BFhr201091_CR26) 2008; 21
G Whitlock (BFhr201091_CR2) 2009; 373
M De Marco (BFhr201091_CR21) 2009; 54
D Gu (BFhr201091_CR27) 2009; 27
CS Fox (BFhr201091_CR3) 2007; 116
WP Castelli (BFhr201091_CR7) 1977; 55
RS Vasan (BFhr201091_CR20) 2001; 358
TS Ferguson (BFhr201091_CR24) 2008; 8
A Hozawa (BFhr201091_CR28) 2009; 22
Prospective Studies Collaboration (BFhr201091_CR19) 2002; 360
F Halberg (BFhr201091_CR31) 2006; 4
References_xml – volume: 358
  start-page: 1682
  year: 2001
  ident: BFhr201091_CR20
  publication-title: Lancet
  doi: 10.1016/S0140-6736(01)06710-1
– volume: 18
  start-page: 515
  year: 2008
  ident: BFhr201091_CR23
  publication-title: Ann Epidemiol
  doi: 10.1016/j.annepidem.2007.11.013
– volume: 8
  start-page: 20
  year: 2008
  ident: BFhr201091_CR24
  publication-title: BMC Cardiovasc Disord
  doi: 10.1186/1471-2261-8-20
– volume: 85
  start-page: 37
  year: 1992
  ident: BFhr201091_CR8
  publication-title: Circulation
  doi: 10.1161/01.CIR.85.1.37
– volume: 31
  start-page: 1323
  year: 2008
  ident: BFhr201091_CR25
  publication-title: Hypertens Res
  doi: 10.1291/hypres.31.1323
– volume: 116
  start-page: 39
  year: 2007
  ident: BFhr201091_CR3
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.106.675355
– volume: 15
  start-page: 539
  year: 1998
  ident: BFhr201091_CR12
  publication-title: Diabet Med
  doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
– volume: 19
  start-page: 139
  year: 2008
  ident: BFhr201091_CR33
  publication-title: Coron Artery Dis
  doi: 10.1097/MCA.0b013e3282f3fbde
– volume: 33
  start-page: 283
  year: 2004
  ident: BFhr201091_CR11
  publication-title: Endocrinol Metab Clin North Am
  doi: 10.1016/j.ecl.2004.03.002
– volume: 29
  start-page: 998
  year: 2006
  ident: BFhr201091_CR9
  publication-title: Diabetes Care
  doi: 10.2337/dc05-1902
– volume: 4
  start-page: 1
  year: 2006
  ident: BFhr201091_CR31
  publication-title: J Appl Biomed
  doi: 10.32725/jab.2006.001
– ident: BFhr201091_CR18
– volume: 289
  start-page: 2560
  year: 2003
  ident: BFhr201091_CR15
  publication-title: JAMA
  doi: 10.1001/jama.289.19.2560
– volume: 83
  start-page: 1237
  year: 2006
  ident: BFhr201091_CR16
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/83.6.1237
– ident: BFhr201091_CR14
– volume: 94
  start-page: 1496
  year: 2004
  ident: BFhr201091_CR22
  publication-title: Am J Cardiology
  doi: 10.1016/j.amjcard.2004.08.026
– volume: 12
  start-page: 1336
  year: 1992
  ident: BFhr201091_CR6
  publication-title: Arterioscler Thromb
  doi: 10.1161/01.ATV.12.11.1336
– volume: 285
  start-page: 2486
  year: 2001
  ident: BFhr201091_CR13
  publication-title: JAMA
  doi: 10.1001/jama.285.19.2486
– volume: 54
  start-page: 974
  year: 2009
  ident: BFhr201091_CR21
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.109.129031
– volume: 27
  start-page: 721
  year: 2009
  ident: BFhr201091_CR27
  publication-title: J Hypertens
  doi: 10.1097/HJH.0b013e328323ad89
– volume: 4
  start-page: 73
  year: 2006
  ident: BFhr201091_CR32
  publication-title: J Appl Biomed
  doi: 10.32725/jab.2006.007
– volume: 22
  start-page: 627
  year: 2008
  ident: BFhr201091_CR10
  publication-title: J Hum Hypertens
  doi: 10.1038/jhh.2008.32
– volume: 53
  start-page: 388
  year: 2009
  ident: BFhr201091_CR34
  publication-title: J Cardiovasc Pharmacol
  doi: 10.1097/FJC.0b013e3181a02238
– volume: 120
  start-page: S10
  issue: 9 Suppl 1
  year: 2007
  ident: BFhr201091_CR5
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2007.06.006
– ident: BFhr201091_CR30
– volume: 22
  start-page: 267
  year: 2009
  ident: BFhr201091_CR28
  publication-title: Am J Hypertens
  doi: 10.1038/ajh.2008.335
– volume: 360
  start-page: 1903
  year: 2002
  ident: BFhr201091_CR19
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)11911-8
– volume: 99
  start-page: 369
  year: 2007
  ident: BFhr201091_CR4
  publication-title: Am J Cardiol
  doi: 10.1016/j.amjcard.2006.08.041
– volume: 360
  start-page: 1903
  year: 2002
  ident: BFhr201091_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)11911-8
– volume: 21
  start-page: 890
  year: 2008
  ident: BFhr201091_CR26
  publication-title: Am J Hypertens
  doi: 10.1038/ajh.2008.212
– volume: 55
  start-page: 767
  year: 1977
  ident: BFhr201091_CR7
  publication-title: Circulation
  doi: 10.1161/01.CIR.55.5.767
– ident: BFhr201091_CR17
– volume: 8
  start-page: 108
  year: 2008
  ident: BFhr201091_CR29
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-8-108
– volume: 373
  start-page: 1083
  year: 2009
  ident: BFhr201091_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(09)60318-4
SSID ssj0028591
Score 2.2424781
Snippet Cardiovascular disease (CVD) is the leading cause of death worldwide. Understandably, cardiometabolic risk assessment is an integral component of every adult...
SourceID proquest
pubmed
crossref
springer
nii
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 905
SubjectTerms 692/53
692/699/75/243
692/700/139
692/700/459
Adult
Aged
Biomarkers - blood
Blood Glucose - analysis
Blood Glucose - metabolism
Blood Pressure
BMI
Body Mass Index
C-Reactive Protein - analysis
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - metabolism
Cholesterol - blood
CRP
Female
Geriatrics/Gerontology
Glycated Hemoglobin A - analysis
Health Promotion and Disease Prevention
Humans
Insulin - blood
insulin resistance
Internal Medicine
Male
Medicine
Medicine & Public Health
metabolic syndrome
Middle Aged
Nutrition Surveys - statistics & numerical data
Obstetrics/Perinatology/Midwifery
original-article
Prehypertension - epidemiology
Prehypertension - metabolism
Prevalence
Public Health
Risk Factors
Sex Factors
Triglycerides - blood
United States - epidemiology
Waist Circumference
Young Adult
Title Prehypertension in disease-free adults : a marker for an adverse cardiometabolic risk profile
URI https://cir.nii.ac.jp/crid/1571417125954476928
https://link.springer.com/article/10.1038/hr.2010.91
https://www.ncbi.nlm.nih.gov/pubmed/20535113
https://www.proquest.com/docview/753994916
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa6TUK8IO4rMGSJvaAqUMeXJLx1U7dqot0ErRgPKMrFodVYitL2hf_D_-Sc2EmzrojLSxRFlhPlfHE-n_P5MyGHma8jP0i1E3FfOSJi0vEzlzmZmwBEEgEMGVMDw5EaTMTZpbxstX42VEurZfwm-bF1Xcn_RBWuQVxxlew_RLbuFC7AOcQXjhBhOP5VjC8KPYV5ZFGq0I1m0RZcnKzQ2phrLDpmQfM1CnEKq5rE2j8QPxR9oR71Wi8BDOh3XUrN7UbeTeI6aN7HOgRNy57rtZWYgr-xYcDvLCqQ657BTxo3v6xlo1hQaNyj1gVNLsZYSJhfrROyw-PT9-ejfmeov07X4D790O-PPvU-l1z8qlMntdE6_OP5qPKfsBJnm-jAGn1QJTpsxpIpB8YL1Ry8jYuGBWnQGImDrmz81AOjnb31vzDu8NPCaPzMvmEb_tvoUas8YElS7ZA91_NQDbDXOzk6GtUzezQBLE0d7RNWPrjcf7vu-wbz2clns22TmlsF-ZLnjO-Te3aCQnsGbQ9IS-cPyZ2hlWA8Il82QEdnOW2CjhrQ0Xc0ogZyFCBHo5xayNENyFGEHLWQe0wmJ_3x8cCxe3Q4iWBs6XCg38CgY6WlTtwUuE0SdFUKs1iueCxVlsKEVMcJjz0JIXGFTL1IdTnXKkhFrPkTspvPc71PaJSpKEqZSICEiwSoJzRwE-m5acrgimyT19X7CxNrYI_7qHwLSyEF98NpEeK7DgPWJq_qtt-NbcvWVgcQBugMj0x6TDAPCH8ghfBU4PptQqsAhTDqYikNPo35ahF6aOgsINxt8tQErr6Ni45JjPE2OawiGdpPbLHlGZ794Rmek7vrj-EF2V0WK30APHgZv7Qo_AXcV7A8
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prehypertension+in+disease-free+adults+%3A+a+marker+for+an+adverse+cardiometabolic+risk+profile&rft.jtitle=Hypertension+research+%3A+clinical+and+experimental+%3A+official+journal+of+the+Japanese+Society+of+Hypertension&rft.au=GUPTA+Alok+K&rft.au=MCGLONE+Meghan&rft.au=GREENWAY+Frank+L&rft.au=JOHNSON+William+D&rft.date=2010-09-01&rft.issn=0916-9636&rft.volume=33&rft.issue=9&rft.spage=905&rft.epage=910&rft_id=info:doi/10.1038%2Fhr.2010.91&rft.externalDocID=10026711056
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0916-9636&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0916-9636&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0916-9636&client=summon